🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thank you Pat Marsteller for an inspiring discussion about wicked problems in #STEMeducation. #Biome2024

Excited about the positive energy on the last day of the #BIOME2024. Looking forward to the #workinggroup and #FMN s this fall.

Join in this webinar to bring RCSB.org and related rata, tools, and resources into your classroom. Register for free today rcsb.org/news/feature/6… #enzymes #molecularmedicine

Have questions about biomolecular visualization using RCSB.org Mol*? Share your #questions and register here (forms.gle/qBJeoVf8cxJTuE…) to join us in the next Office Hour on Sep 9, 2024 at 1p ET. Learn more at rcsb.org/news/feature/6…

Join us on Nov 4, 2024 @ 1p ET for this year's last Mol* Office Hour to explore #Plant (e.g., rice, lupine, peanuts, and more) proteins. Register (forms.gle/qBJeoVf8cxJTuE…). Learn more at rcsb.org/news/feature/6… Abdulkabir Omeiza The Pop Scientist Rajarshi Sanyal Plantae

It is free to attend but you have to register forms.gle/qBJeoVf8cxJTuE…. Hope you can join us on Nov 4, 2024 at 1p ET to visualize and #explore #Plant #protein

Metformin bound to SLC22A1, a transporter involved in uptake of the #diabetes treatment medicine metformin. see PDB ID 8jtt (rcsb.org/structure/8JTT). #WorldDiabetesDay2024

Congratulations Caleb M. Trujillo on the publication of this blog about #MolCaseNet. uwb.edu/news/2024/11/2… #storytelling

Last month U.S. FDA approved the 1st biparatopic antibody therapy (Zanidatamab) for metastatic HER2+ billiary tranct #Cancer. The bispecific antibodies simultaneously targets 2 regions of HER2 - dimerization & extracellular juxtamembrane domains, nature.com/articles/d4157…

Thank you Dr. Tracie Addy for organizing the community reading on Enhancing #inclusive Instruction this semester. I am inspired to learn more and apply this learning.

Acute leukaemias require chromatin adapter protein menin (MEN1 gene product) function. Last month, menin inhibitor revumenib was approved by U.S. FDA for treating refractory acute leukemia.

In October U.S. FDA approved inavolisib, a PI3Kα Inhibitor to treat locally advanced or metastatic breast #Cancer. It was approved for use with with palbociclib and fulvestrant.

Human TCR and HLA-A1 major histocompatibility complex (MHC) can recognize NRAS neoantigens peptides with Q61K and Q61R mutations versus wild-type NRAS peptide. #cancer #AlphaFold

Lazertinib a tyrosine kinase inhibitor (TKI) was approved by U.S. FDA in Aug 2024 for EGFR mutant (e.g., L858R/T790M) non-small cell lung #cancer. It is is used alone or in combination with other #chemotherapeutic agents.

Tovorafenib, a type II RAF kinase inhibitor was approved by U.S. FDA to treat a type of brain tumour in children - e.g., relapsed or refractory pediatric low-grade glioma esp. with BRAF gene mutations (e.g., V600E). #Cancer #BRAIN

With gratitude for what I have learned in the past years I welcome a new chapter in 2025. #MolecularStorytelling #scicomm #MolecularVisualization

Many gastrointestinal #Cancer are driven mutant KIT tyrosine kinase. Commonly treated with type II KIT inhibitors (eg, imatinib and sunitinib), adding type I or active-state KIT inhibitor (eg, pexidartinib) can broad mutation coverage. U.S. FDA #Storytelling

Gabapentin (magenta) was approved by U.S. FDA as an anti-epileptic & for treating seizures. It inhibits voltage-gated calcium channels & is also widely used to treat neuropathic pain. (calcium shown as red sphere) doi.org/10.1038/s41594…

O-GlcNAcylation, a post-translational modification of tau & other proteins, is decreased in #Alzheimers disease. Ceperognastat, inhibits O-GlcNAcase, and enzyme that catalyzes the removal of O-GlcNAc from tau, so it can slow progression of the disease!

Nipah #virus is bat-borne & highly pathogenic in humans. Structures of the viral polymerase complex (polymerase, L & phosphoprotein, P), provide insights for rational design of antiviral drugs. doi.org/10.1016/j.cell…; doi.org/10.1038/s44318…